Pharmaceutical research is undergoing a structural transformation as regulatory agencies demand greater data integrity and traceability, and the industry shifts from retrospective audits to continuous, AI-enabled monitoring systems. At the same time, drug discovery is being reshaped by large-scale biomedical data and tools to interrogate it. Oncotelic Therapeutics (OTCQB: OTLC) has responded with PDAOAI, an evidence-interrogation platform designed to surface testable research hypotheses from the global TGF-β literature.
Unlike traditional predictive models that replicate historical datasets, PDAOAI takes a retrieval-and-interrogation approach. It indexes over 125,000 PubMed abstracts on TGF-β signaling, allowing researchers to identify patterns and generate hypotheses with direct links to evidence. This hypothesis-first method aims to reduce training-set bias and build transparent, reproducible chains from question to evidence to hypothesis—a core challenge in biotech research.
Recent industry coverage places Oncotelic alongside Rockwell Automation, Emerson Electric, Thermo Fisher Scientific, and Danaher as contributors to the pharmaceutical sector's shift toward AI-integrated operations. The platform's emphasis on transparent, auditable hypotheses could have significant implications for drug development, where regulatory expectations increasingly require defensible documentation.
For business and technology leaders, the PDAOAI platform highlights a growing trend: manual processes and isolated datasets are no longer sufficient in an environment where scientific literature expands rapidly. The ability to interrogate evidence at scale could accelerate research while maintaining compliance. As AI adoption in pharma accelerates, platforms that prioritize transparency and traceability may become essential tools for reducing risk and improving outcomes.
